Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review

被引：27
作者：
Diedhiou, Demba [1 ,2 ]
Cuny, Thomas [1 ]
Sarr, Anna [2 ]
Diop, Said Norou [2 ]
Klein, Marc [1 ]
Weryha, Georges [1 ]
机构：
[1] Lorraine Univ, Univ Hosp Ctr Nancy, Dept Endocrinol, Vandoeuvre Les Nancy, France
[2] Cheikh Anta Diop Univ, Univ Hosp Ctr Dakar, Dept Internal Med 2, Dakar, Senegal
来源：
ANNALES D ENDOCRINOLOGIE | 2015年 / 76卷 / 06期
关键词：
Osteoporosis; Denosumab; Fracture risk; Renal insufficiency; Safety; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; TURNOVER MARKERS; RISK REDUCTION; FRACTURE RISK; ALENDRONATE; THERAPY; MASS; PHASE-2;
D O I：
10.1016/j.ando.2015.10.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Denosumab is an anti-RANK ligand (RANKL) monoclonal antibody approved for the treatment of postmenopausal osteoporosis and prevention of skeletal metastasis complications. Administered subcutaneously every 6 months, it reduces the risk of vertebral fracture by 70% and of hip fracture by 40%. Its safety profile is acceptable. Denosumab may be used to treat patients with moderate to severe renal insufficiency. It has anti-fracture activity equivalent to that of zoledronic acid, but no residual effect, and no action at all beyond 6 months. In France, denosumab is reimbursed as a second-line treatment after a first attempt with bisphosphonate. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：650 / 657
页数：8
相关论文
共 50 条
[31]   Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis [J].
Yuan, Chuanjian ;
Liang, Yanchen ;
Zhu, Kai ;
Xie, Wenpeng .
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2023, 18 (01)
[32]   Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis [J].
Feng, Shi ;
Luo, Zhicheng ;
Liu, Da .
JOURNAL OF BONE AND MINERAL METABOLISM, 2015, 33 (04) :448-454
[33]   Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis [J].
Kocjan, Tomaz ;
Rajic, Antonela Sabati ;
Janez, Andrej ;
Vidmar, Gaj ;
Orehek, Nina ;
Marc, Janja ;
Ostanek, Barbara .
ENDOCRINE PRACTICE, 2021, 27 (09) :941-947
[34]   Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review [J].
Nargesi, Shahin ;
Barghazan, Saeed Husseini ;
Sani'ee, Nadia ;
Kemmak, Asma Rashki .
IRANIAN JOURNAL OF PUBLIC HEALTH, 2022, 51 (07) :1502-1512
[35]   A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis [J].
Singh, S. ;
Dutta, S. ;
Khasbage, S. ;
Kumar, T. ;
Sachin, J. ;
Sharma, J. ;
Varthya, S. B. .
OSTEOPOROSIS INTERNATIONAL, 2022, 33 (01) :1-12
[36]   Effects of denosumab treatment in chronic liver disease patients with osteoporosis [J].
Saeki, Chisato ;
Saito, Mitsuru ;
Oikawa, Tsunekazu ;
Nakano, Masanori ;
Torisu, Yuichi ;
Saruta, Masayuki ;
Tsubota, Akihito .
WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (33) :4960-4971
[37]   A review of denosumab for the treatment of osteoporosis [J].
Miyazaki, Tsuyoshi ;
Tokimura, Fumiaki ;
Tanaka, Sakae .
PATIENT PREFERENCE AND ADHERENCE, 2014, 8 :463-471
[38]   The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials [J].
Su, S. ;
He, N. ;
Men, P. ;
Song, C. ;
Zhai, S. .
OSTEOPOROSIS INTERNATIONAL, 2019, 30 (06) :1175-1186
[39]   Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety [J].
Aquila Gopaul ;
Tharsan Kanagalingam ;
Jenny Thain ;
Tayyab Khan ;
Andrea Cowan ;
Nabil Sultan ;
Kristin K. Clemens .
Archives of Osteoporosis, 2021, 16
[40]   Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis [J].
Yang, Jiwon ;
Park, Youngjae ;
Lee, Jennifer Jooha ;
Kwok, Seung-Ki ;
Ju, Ji Hyeon ;
Kim, Wan-Uk ;
Park, Sung-Hwan .
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2025, 17
12345